Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study
Background Several anti-cytokine therapies were tested in the randomized trials in hospitalized patients with severe acute respiratory syndrome coronavirus 2 infection (COVID-19). Previously, dexamethasone demonstrated a reduction of case-fatality rate in hospitalized patients with respiratory failu...
Uložené v:
| Vydané v: | BMC infectious diseases Ročník 21; číslo 1; s. 1277 - 9 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
22.12.2021
BioMed Central Ltd Springer Nature B.V BMC |
| Predmet: | |
| ISSN: | 1471-2334, 1471-2334 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
Buďte prvý, kto okomentuje tento záznam!